Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharma Mar SA ( (ES:PHM) ) just unveiled an announcement.
Sylentis, a subsidiary of Pharma Mar, has been awarded a 21.1 million euro grant from the European Commission under the IPCEI ‘Med4Cure’ program. This funding will support the SYOLIGO project, which involves the construction of a new pharmaceutical plant in Getafe, Spain, for the production of RNA-based drugs and treatments for rare diseases. The project is expected to create 86 direct and 350 indirect jobs by 2030, enhancing Spain’s pharmaceutical capabilities and fostering collaboration with European partners.
More about Pharma Mar SA
Pharma Mar S.A. is a company operating in the pharmaceutical industry, focusing on the development and production of RNA-based drugs and treatments for rare diseases. Its subsidiary, Sylentis, is involved in cutting-edge research and innovation, with a market focus on rare diseases and third-party manufacturing of RNA-based drugs.
YTD Price Performance: 14.11%
Average Trading Volume: 1,084
Technical Sentiment Signal: Sell
Current Market Cap: $1.72B
See more data about PHM stock on TipRanks’ Stock Analysis page.